Allergan PLC. (AGN) Shares Bought by Vanguard Group Inc.
Vanguard Group Inc. boosted its holdings in Allergan PLC. (NYSE:AGN) by 2.2% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 22,835,689 shares of the company’s stock after buying an additional 482,220 shares during the period. Vanguard Group Inc. owned approximately 6.80% of Allergan PLC. worth $5,551,128,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the business. Northern Trust Corp increased its position in Allergan PLC. by 8.8% in the 2nd quarter. Northern Trust Corp now owns 4,492,944 shares of the company’s stock worth $1,092,189,000 after buying an additional 364,722 shares during the period. Marietta Wealth Management LLC lifted its holdings in shares of Allergan PLC. by 20.8% during the second quarter. Marietta Wealth Management LLC now owns 6,491 shares of the company’s stock worth $1,578,000 after buying an additional 1,116 shares during the last quarter. Gluskin Sheff & Assoc Inc. lifted its holdings in shares of Allergan PLC. by 59.5% during the second quarter. Gluskin Sheff & Assoc Inc. now owns 103,681 shares of the company’s stock worth $25,204,000 after buying an additional 38,683 shares during the last quarter. Pacific Center for Financial Services boosted its position in shares of Allergan PLC. by 1.3% in the second quarter. Pacific Center for Financial Services now owns 541 shares of the company’s stock valued at $132,000 after acquiring an additional 7 shares during the period. Finally, Pathstone Family Office LLC boosted its position in shares of Allergan PLC. by 3,327.3% in the second quarter. Pathstone Family Office LLC now owns 377 shares of the company’s stock valued at $2,035,000 after acquiring an additional 366 shares during the period. 82.03% of the stock is currently owned by institutional investors.
Allergan PLC. (NYSE AGN) opened at 209.80 on Wednesday. Allergan PLC. has a one year low of $184.50 and a one year high of $256.80. The company’s 50-day moving average is $220.20 and its 200 day moving average is $233.72. The company has a market capitalization of $70.14 billion, a P/E ratio of 6.39 and a beta of 1.15.
Allergan PLC. (NYSE:AGN) last announced its earnings results on Thursday, August 3rd. The company reported $4.02 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $3.95 by $0.07. Allergan PLC. had a net margin of 79.17% and a return on equity of 7.37%. The company had revenue of $4.01 billion for the quarter, compared to analysts’ expectations of $3.95 billion. During the same period last year, the firm earned $3.35 earnings per share. The business’s revenue for the quarter was up 8.8% on a year-over-year basis. Analysts predict that Allergan PLC. will post $16.22 EPS for the current year.
Allergan PLC. declared that its board has approved a share buyback program on Monday, September 25th that authorizes the company to buyback $2.00 billion in outstanding shares. This buyback authorization authorizes the company to reacquire up to 2.8% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its shares are undervalued.
The business also recently declared a quarterly dividend, which was paid on Friday, September 15th. Investors of record on Friday, August 18th were paid a $0.70 dividend. This represents a $2.80 annualized dividend and a dividend yield of 1.33%. The ex-dividend date was Wednesday, August 16th. Allergan PLC.’s dividend payout ratio (DPR) is currently 9.95%.
AGN has been the topic of several research analyst reports. Wells Fargo & Company restated a “buy” rating on shares of Allergan PLC. in a research note on Monday. Barclays PLC reaffirmed an “equal weight” rating on shares of Allergan PLC. in a research report on Monday. UBS AG reiterated a “buy” rating and set a $275.00 target price on shares of Allergan PLC. in a research note on Tuesday, September 26th. Credit Suisse Group reiterated an “outperform” rating and set a $266.00 target price (down from $286.00) on shares of Allergan PLC. in a research note on Tuesday, September 26th. Finally, Mizuho reiterated a “buy” rating and set a $267.00 target price on shares of Allergan PLC. in a research note on Monday, September 25th. One research analyst has rated the stock with a sell rating, eight have assigned a hold rating and fourteen have issued a buy rating to the company. Allergan PLC. has a consensus rating of “Buy” and a consensus price target of $271.84.
TRADEMARK VIOLATION NOTICE: “Allergan PLC. (AGN) Shares Bought by Vanguard Group Inc.” was published by Marea Informative and is the property of of Marea Informative. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at http://www.mareainformativa.com/allergan-plc-agn-shares-bought-by-vanguard-group-inc/115324/.
Allergan PLC. Company Profile
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Receive News & Stock Ratings for Allergan PLC. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC. and related stocks with our FREE daily email newsletter.